HNK20: ORVX started a double-blind, placebo-controlled Phase III study of its HNK20 monoclonal antibody

OraVax Inc. (ORVX), Cambridge, Mass. Product: HNK20, monoclonal antibody Indication: Prevent respiratory syncytial virus (RSV) Status: ORVX started a double-blind, placebo-controlled Phase III study o...